Daily non-political popular news in brief.
New therapeutic target for Alzheimer's could lead to drugs without side effects
02-26-2007 · EurekAlert!New research from Rockefeller University, published in the Feb. 26 online edition of Proceedings of the National Academy of Sciences, has identified a therapeutic target, called casein kinase 1, that may be the key to halting the course of the disease. The findings, based on studies in mammalian cells, show that chemicals that block casein kinase 1 don't interfere with a closely connected essential pathway.
Read more »
Keywords: therapeutic, target, alzheimer, lead, drugs, side, effects, drug, effect
« Previous | Next »
Similar news on "New therapeutic target for Alzheimer's could lead to drugs without side effects":
- Study: Re-engineered Gleevec reduces heart risks
12-03-2007 · EurekAlert!
Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib -- best known by its brand name Gleevec -- to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect. The re-design strategy employed in the study is broadly applicable to reducing side effects in other drugs.
Similar news · Read more »
- Sunshine pill for prostate cancer in 2009
01-16-2007 · EurekAlert!
A drug based on vitamin D and is given to patients in the advanced stages of prostate cancer along with chemotherapy drugs could be availiable by 2009. Vitamin D from sunlight improves the prognosis of certain cancers, but taking natural levels of the vitamin has no effect. Novacea, the company that makes Asentar, produced a novel formulation that reproduces the healing effect without the dangerous side-effects of a vitamin D overdose.
Similar news · Read more »
- OCT1 required for therapeutic effects of diabetes drug Metformin
05-01-2007 · EurekAlert!
Metformin is among the most widely prescribed drugs for the treatment of type 2 diabetes. Mouse and human studies led by Kathleen Giacomini from the University of California, San Francisco, and reported in the May 1 issue of the JCI indicate that organic cation transporter 1 is important in mediating the therapeutic effects of metformin and that genetic variation in OCT1 in diabetics may contribute to the varied patient responses to this drug.
Similar news · Read more »
- Possible safer target for anti-clotting drugs found
09-26-2007 · EurekAlert!
Researchers at the University of Illinois at Chicago College of Medicine have identified a new molecular target in the process of blood clot formation, which seems to reduce clotting without excessive bleeding, the common side-effect of anti-clotting agents.
Similar news · Read more »
- Protein inhibitor tangles with Alzheimer's disease
02-15-2007 · EurekAlert!
A hallmark of Alzheimer's disease (AD) is the abnormal accumulation of phosphorylated forms of a protein known as tau. In a new study, Mayo Clinic researchers have now shown in mice that a drug that inhibits the function of the protein Hsp90 (EC102) reduces the amount of phosphorylated tau in the brain. Unlike many drugs, EC102 is able to cross the blood-brain barrier, making it a highly promising therapeutic candidate for AD.
Similar news · Read more »
- M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
12-11-2006 · EurekAlert!
Researchers at the University of Texas M. D. Anderson Cancer Center reported today that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients.
Similar news · Read more »
- New alzheimer's drug shows promise in clinical trial
11-02-2006 · EurekAlert!
The only drugs currently available for Alzheimer's patients are those that alleviate symptoms, but a team of scientists led by Paul Aisen, MD, director of the Memory Disorders program at Georgetown University Medical Center, is testing a new class of drugs that actually target the molecule believed to cause the disease.
Similar news · Read more »
- A new computational technique predicts side-effects of a major cancer drug
11-27-2007 · EurekAlert!
Researchers at the University of California San Diego have developed a novel computer technique to search for the side effects of major pharmaceuticals. The study, reported Nov. 30 in PLoS Computational Biology, relates to a class of drugs known as Select Estrogen Receptor Modulators, which includes tamoxifen, the most prescribed drug in the treatment of breast cancer.
Similar news · Read more »
- New computational technique can predict drug side effects
12-11-2007 · EurekAlert!
Early identification of adverse effects of drugs before they are tested in humans is crucial in developing new therapeutics, as unexpected effects account for a third of all drug failures during the development process. Now researchers at the University of California-San Diego have developed a novel technique using computer modeling to identify potential side effects of pharmaceuticals, and have used the technique to study a class of drugs that includes tamoxifen.
Similar news · Read more »
- Cancer drug side effect caused by cell 'pump' problem
12-05-2006 · EurekAlert!
A troublesome side effect caused by some cancer drugs appears to be caused by a broken "pump" in the liver that fails to push these medicines into a "drain," according to investigators at St. Jude Children's Research Hospital.
Similar news · Read more »
